bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
243 hedge funds and large institutions have $6.9B invested in bluebird bio in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 105 increasing their positions, 61 reducing their positions, and 39 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 61
48% more call options, than puts
Call options by funds: $163M | Put options by funds: $110M
33% more capital invested
Capital invested by funds: $5.17B → $6.9B (+$1.72B)
15% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 39
1% more funds holding
Funds holding: 241 → 243 (+2)
0% more ownership
Funds ownership: 8.51% → 8.51% (+0%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.4M |
| 2 |
BlackRock
New York
|
+$30.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$26.7M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.4M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$24.2M |
| 2 |
Goldman Sachs
New York
|
-$22.3M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$21.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.6M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$17M |
BLUE Hedge Fund Activity: Q3 2017 in Review
243 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2017, worth a combined $6.9B — up 33% from $5.17B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BLUE positions and 39 closed out — a net gain of 6 holders — while 105 added to existing stakes and 61 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $38.4M. The largest seller was Victory Capital Management, cutting an estimated $24.2M.
- 243 institutional investors held bluebird bio (BLUE) as of Q3 2017, up from 241 in Q2 2017.
- Funds reported $6.9B of bluebird bio stock for Q3 2017, up 33% quarter-over-quarter.
- 45 funds opened new bluebird bio positions in Q3 2017 and 39 closed out, a net change of +6 holders.
- The largest bluebird bio buyer in Q3 2017 was Wellington Management Group, an estimated $38.4M added.
- The largest bluebird bio seller in Q3 2017 was Victory Capital Management, an estimated $24.2M sold.
Based on aggregated 13F filings for Q3 2017.